Diamyd Medical receives approval from the Swedish Medical Products Agency for the Phase II trial DIAGNODE-2

The Swedish Medical Products Agency has approved the conduction of DIAGNODE-2, a pivotal follow-up clinical trial in children and adolescents recently diagnosed with type 1 diabetes.The placebo-controlled Phase II trial DIAGNODE-2 will investigate an innovative and patent-pending concept, where the diabetes vaccine Diamyd® is administered directly into the lymph node. Submission of applications to the respective Competent Authorities in Spain and the Czech Republic are ongoing, as well as to the relevant Ethics Committees. The clinical trial is expected to commence patient recruitment by